Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 03, 2015 8:05 AM ET

Biotechnology

Company Overview of Innovacell Biotechnologie AG

Company Overview

Innovacell Biotechnologie AG, a biotechnology company, develops personalized cell therapies for treatment of incontinence. It provides ICES13 and ICEF15, cell-based therapy products for treatment of stress urinary incontinence and faecal incontinence, respectively. The company was founded in 2000 and is based in Innsbruck, Austria with laboratory and productions facilities in Innsbruck, Austria.

Life Science Center

Mitterweg 24

Innsbruck,  6020

Austria

Founded in 2000

Phone:

43 512 - 573680

Fax:

43 512 - 573680-5

Key Executives for Innovacell Biotechnologie AG

Chief Executive Officer
Managing Director
Founder and Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Innovacell Biotechnologie AG Key Developments

Innovacell Biotechnologie AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Innovacell Biotechnologie AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Norgine B.V. and Innovacell Enter into an Exclusive Licensing Agreement for ICEF15

Norgine B.V. and Innovacell announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in First Quarter 2014. ICEF15 is developed for both men and women suffering from faecal incontinence with sphincter weakness or damage. ICEF15 is a personalised cell-based product concept based upon proliferating autologous myoblasts from a biopsy taken from the patients' own muscle. The patient's proliferated muscle cells are re-injected into the patient's external anal sphincter muscle, using Innovacell's proprietary injection device, thereby regenerating the muscle's full functionality.

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 10, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Innovacell Biotechnologie AG, please visit www.innovacell.at. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.